<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A 77-year-old man was diagnosed as having <z:e sem="disease" ids="C0040028" disease_type="Disease or Syndrome" abbrv="">essential thrombocythemia</z:e> (ET) in 1994 </plain></SENT>
<SENT sid="1" pm="."><plain>He had been treated with <z:chebi fb="0" ids="44423">hydroxyurea</z:chebi> (HU) for six years, and 9 years after the diagnosis of ET, he then developed <z:hpo ids='HP_0004820'>acute myelomonocytic leukemia</z:hpo> (AMMoL) following <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) </plain></SENT>
<SENT sid="2" pm="."><plain>Since he suffered from <z:e sem="disease" ids="C0151744" disease_type="Disease or Syndrome" abbrv="IHD">ischemic heart disease</z:e>, we chose the ara-C+<z:chebi fb="0" ids="4911">VP-16</z:chebi> therapy </plain></SENT>
<SENT sid="3" pm="."><plain>Two courses of the ara-C+<z:chebi fb="0" ids="4911">VP-16</z:chebi> therapy resulted in partial remission in the bone marrow and a prolonged hematological response </plain></SENT>
<SENT sid="4" pm="."><plain>This case seemed rare, since in previous reports, prognosis of ET patients developing <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> was very poor and most of the patients expired within six months </plain></SENT>
</text></document>